Immuno-Oncology | Specialty

Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma

June 2nd 2014

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

Dr. Fong Discusses Intratumoral Electroporation of Plasmid IL-12 in Melanoma

June 2nd 2014

Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Investigational Immunotherapy Granted First Breakthrough Therapy Designation in Bladder Cancer

June 1st 2014

MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.

Dr. Pavlick on a Phase II Trial of Cyclophosphamide and Ipilimumab in Melanoma

May 28th 2014

Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

May 27th 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Nivolumab, Elotuzumab Receive Breakthrough Therapy Designations for Types of Blood Cancer

May 19th 2014

Over the course of only a few days, two drugs that will be commercialized by Bristol-Myers Squibb (BMS), nivolumab and elotuzumab, have each been granted breakthrough therapy designations by the FDA for the treatment of two different types of blood cancers.

Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC

May 16th 2014

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Dr. Litzow on New Immunologic Therapies in ALL

May 15th 2014

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Rosenberg Discusses the Curative Potential of Cancer Immunotherapy

May 13th 2014

Steven A. Rosenberg, MD, PhD, Chief of Surgery at the National Cancer Institute, discusses the curative potential of immunotherapy for patients with cancer.

Brentjens Discusses Key Questions in CAR T-Cell Therapies

May 12th 2014

An interview with Renier J. Brentjens, MD, PhD, on new therapies for patients with acute and chronic leukemias, in particular novel immunotherapies such as chimeric antigen receptor T cells.

FDA Grants Priority Review to PD-1 Inhibitor Pembrolizumab in Advanced Melanoma

May 6th 2014

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab (MK-3475) as a treatment for patients with unresectable or metastatic melanoma following progression on ipilimumab.

Dr. Hsieh Discusses New Treatments for Kidney Cancer

April 25th 2014

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

Advances in Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

April 25th 2014

The treatment decisions for NSCLC are primarily dependent on the patient's performance status, extent of disease, and histological subtype. Significant developments in the area of targeted therapies have changed the treatment paradigm for NSCLC.

Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

April 24th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD

April 8th 2014

An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.

PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC

April 7th 2014

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

Aduro BioTech Immunotherapy Duo Shows Promise in Pancreatic Cancer

April 3rd 2014

The use of immunotherapy for pancreatic cancer has had limited exposure, but Aduro BioTech, Inc, has had phase II success with an approach in which two vaccines are administered. The vaccines, GVAX Pancreas and CRS-207, are administered to patients sequentially.

Dr. Halmos on Checkpoint Inhibitors in Lung Cancer

April 2nd 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the anti-PD-L1 antibody MK-3475 and the challenge of integrating immunotherapies into the field of lung cancer.

MAGE-A3 Vaccine Falters in Large Phase III NSCLC Study

April 2nd 2014

The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.